000 | 01698 a2200481 4500 | ||
---|---|---|---|
005 | 20250513175954.0 | ||
264 | 0 | _c19990524 | |
008 | 199905s 0 0 eng d | ||
022 | _a0146-0404 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aGhiso, N | |
245 | 0 | 0 |
_aSuppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. _h[electronic resource] |
260 |
_bInvestigative ophthalmology & visual science _cMay 1999 |
||
300 |
_a1033-9 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 | _a3T3 Cells |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aCell Line |
650 | 0 | 4 |
_aCyclic CMP _xphysiology |
650 | 0 | 4 |
_aEndothelial Growth Factors _xantagonists & inhibitors |
650 | 0 | 4 |
_aEndothelium, Vascular _xcytology |
650 | 0 | 4 |
_aGene Expression _xdrug effects |
650 | 0 | 4 |
_aGenes, ras _xgenetics |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoxia _xgenetics |
650 | 0 | 4 |
_aLymphokines _xantagonists & inhibitors |
650 | 0 | 4 | _aMice |
650 | 0 | 4 |
_aNF-kappa B _xphysiology |
650 | 0 | 4 |
_aNitric Oxide _xphysiology |
650 | 0 | 4 |
_aNitric Oxide Donors _xpharmacology |
650 | 0 | 4 |
_aNitroprusside _xpharmacology |
650 | 0 | 4 |
_aRetina _xcytology |
650 | 0 | 4 |
_aTetradecanoylphorbol Acetate _xpharmacology |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTransfection |
650 | 0 | 4 | _aVascular Endothelial Growth Factor A |
650 | 0 | 4 | _aVascular Endothelial Growth Factors |
700 | 1 | _aRohan, R M | |
700 | 1 | _aAmano, S | |
700 | 1 | _aGarland, R | |
700 | 1 | _aAdamis, A P | |
773 | 0 |
_tInvestigative ophthalmology & visual science _gvol. 40 _gno. 6 _gp. 1033-9 |
|
999 |
_c10194472 _d10194472 |